Merck Failed To Probe Diabetes Drugs For Risks: FDA

Law360, New York (February 28, 2012, 7:08 PM EST) -- The U.S. Food and Drug Administration warned Merck & Co. Inc. that it faces possible fines for missing a deadline by more than a year to probe pancreatitis risks tied to its diabetes drugs Januvia and Janumet, according to a letter released Tuesday.

In the letter, which was dated Feb. 17 and posted to the FDA's website on Tuesday, the FDA said Merck failed to comply with milestone dates to conduct a postmarketing study of Januvia and Janumet and that it could incur civil penalties of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.